OncoMatch/Clinical Trials/NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Is NCT07052253 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TT-00420 (tinengotinib) and AK104 for hepatocellular carcinoma (hcc).
Treatment: TT-00420 (tinengotinib) · AK104 · AK112 — An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, BCLC STAGE B (IF UNSUITABLE FOR CURATIVE TOPICAL TREATMENT) (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C; or stage B and assessed by the investigator as unsuitable for curative topical treatment
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
No prior systemic anti-cancer treatment for hepatocellular carcinoma
Cannot have received: topical treatment for liver cancer
Received topical treatment for liver cancer within 4 weeks prior to the first administration
Cannot have received: systemic anti-tumor drugs
Received any systemic anti-tumor drugs within 4 weeks prior to the first administration
Cannot have received: other clinical trial drugs
Received other clinical trial drugs within 4 weeks prior to the first administration
Lab requirements
Blood counts
adequate bone marrow function
Liver function
child-pugh liver function score ≤7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify